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Introduction: In recent decades, antimicrobial resistance has become a public health problem, 
particularly in cases of healthcare-associated infections. Interaction between antibiotic consump-
tion and resistance development is of particular interest regarding Gram-negative bacilli, whose 
growing resistance has represented a great challenge.
Objective: Assess the impact of restriction of cefepime use on antimicrobial susceptibility 
among the Gram-negative bacilli (GNB) most frequently involved in healthcare-associated 
infections (HAI).
Methods: Data relating to hospital occupancy and mortality rates, incidence of HAI, incidence 
of GNB as causative agents of HAI, antimicrobial consumption at the hospital and antimicrobial 
susceptibility of GNB related to HAI were compared between two periods: a 24-month period 
preceding restriction of cefepime use and a 24-month period subsequent to this restriction.
Results: There was a significant drop in cefepime consumption after its restriction.   Susceptibility 
of Acinetobacter baumanii improved relating to gentamicin, but it worsened in relation to 
imipenem, subsequent to this restriction. For Pseudomonas aeruginosa, there was no change 
in antimicrobial susceptibility. For Klebsiella pneumoniae and Enterobacter spp, there were 
improvements in susceptibility relating to ciprofloxacin.
Conclusion: Restriction of cefepime use had a positive impact on K. pneumoniae and Enterobacter 
spp, given that after this restriction, their susceptibilities to ciprofloxacin improved. However, for 
A. baumanii, the impact was negative, given the worsening of susceptibility to imipenem.
Keywords: ecological studies, cross infection, drug resistance, microbial, Gram-negative 
bacilli, cefepime
Introduction
Over recent decades, resistance to antimicrobials has become a worldwide public health 
problem, and particularly important regarding bacterial agents that cause healthcare 
related infections.1 Today, there are bacteria responsible for infections in hospital 
environments that are resistant to all existing classes of antimicrobials, which shows 
their great potential for evolutionary adaptation.2 This, together with the declining 
numbers of new antimicrobials that are being certified and introduced into clinical 
practice, is making the growing prevalence of these bacteria with high levels of resis-
tance a subject of increasing concern.3 The formerly abundant flow of new antibiotics 
of ever-broader spectrum supplied by the pharmaceutical industry has been shown to 
be a non-renewable resource.4Infection and Drug Resistance 2011:4 submit your manuscript | www.dovepress.com
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The options for attempting to control the dissemination 
of bacterial resistance within hospital settings include educa-
tional policies aimed at better adherence to infection control 
practices among professionals, particularly with regard to 
hand hygiene; and strategies for rationalizing the prescription 
of antimicrobials within hospitals.5–7
It has now become clear that the use of antimicrobials 
favors the emergence of resistant bacterial strains. However, 
it is also known that the genetic mechanism used by bacteria 
to acquire resistance to antibiotics not only promotes their 
spread within hospital environments but also confers stability 
on the resistance genes, even subsequently, in situations of 
absence of exposure to antimicrobials.8
This interaction between antibiotic consumption and the 
development of bacterial resistance to them is of particular 
interest with regard to Gram-negative bacilli (GNB). The 
resistance development pattern of GNB today provides a great 
challenge in treating infections caused by these bacteria. Given 
that new therapeutic options for treating infections caused by 
these GNB with high levels of resistance are not expected to 
become available in the near future, it becomes imperative 
to study measures that might be capable of improving the 
antimicrobial susceptibility of these bacterial agents, thereby 
making it possible to use the drugs that are available. Studies 
showing the effects of modifications to antibiotic prescription 
patterns are especially of interest in relation to combating the 
emergence of resistance in GNB strains.6 The objective of this 
study was to assess the impact of restriction of cefepime use on 
antimicrobial susceptibility among the Gram-negative bacilli 
(GNB) most frequently involved in healthcare-associated 
infections at a tertiary-level orthopedic hospital.
Methods
This observational study of an ecological nature was con-
ducted at the Institute of Orthopedics and Traumatology, 
Hospital das Clínicas, University of São Paulo School of 
Medicine, which provides specialized high-complexity 
tertiary-level care within the field of orthopedics and trau-
matology in the city of São Paulo, Brazil. It was approved 
by the local Ethics Committee under the number 0649/07. At 
the time covered by this study, the hospital had an average 
of 150 beds available for operations, of which ten were for 
intensive care. In May 2007, the standard empirical antibi-
otic therapy for surgical site infections in this hospital was 
changed. This is the main type of hospital infection seen at 
this hospital, because of the attendance profile. Up to this 
date, combination therapy with vancomycin and cefepime 
was the first choice for empirical treatment of these   infections 
until results had been obtained from cultures, and the con-
sumption of both of these drugs was very high. After this 
date, a regime using teicoplanin and amikacin became the 
standard for empirical antibiotic therapy in such cases, and 
the use of cefepime was restricted. For the present study, 
data relating to hospital occupancy and mortality profiles; 
incidence of healthcare-associated infection cases; incidence 
of GNB as the cause of healthcare-associated infection; 
consumption of antimicrobials in the hospital (in defined 
daily doses [DDD]/1000 patient-days); and antimicrobial 
susceptibility for GNB relating to healthcare infection were 
obtained and compared between two periods: a 24-month 
period preceding the restriction on cefepime use, from 
May 2005 to May 2007 (first period); and a 24-month period 
subsequent to introducing the restriction, from May 2007 to 
May 2009 (second period).
For this study, the criteria for defining nosocomial infec-
tion recommended by the Centers for Disease Control and 
Prevention (CDC) in 2004 were used.10 For the analysis, only 
the GNB for which more than 30 isolates were obtained in 
each of the two study periods were selected, in accordance 
with the norms recommended by the Clinical and Laboratory 
Standards Institute (CLSI) for analysis and interpretation of 
cumulative antibiograms.11 The institutional policies for con-
trolling healthcare-associated infections remained the same 
throughout the two periods. To meet the study objectives, 
the consumption of each antimicrobial was described sepa-
rately and per class using summary measurements for each 
of the two periods (prior and subsequent to the restriction of 
cefepime use), and comparisons were made between the peri-
ods using the nonparametric Mann–Whitney test.12 Hospital 
occupancy and mortality measurements were described and 
compared in the same manner. Measurements of the antimi-
crobial susceptibility for each of the selected microorganisms 
were made according to the period, using absolute and relative 
frequencies, and the presence of associations in each period 
was investigated by means of the chi-square test, or by means 
of the Fisher exact test when the sample was very small.12 The 
tests were conducted using a significance level of 5%.
Results
There were no differences between the two periods regard-
ing the mean length of hospital stay or the mean hospital 
mortality rate, and there was no significant difference in the 
incidence of healthcare-associated infection cases between 
the two periods. The incidence of GNB as the cause of 
healthcare-associated infection also did not vary significantly 
between the two study periods (Table 1).Infection and Drug Resistance 2011:4 submit your manuscript | www.dovepress.com
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Table 1 Comparison between the patients’ mean length of hospital stay, and the mean hospital mortality rates, (defined as the mean 
hAI rates and the numbers of gnB isolates relating to hAI), between the periods before and after restriction on cefepime use
24-month period preceding  
restriction on cefepime use
24-month period subsequent  
to restriction on cefepime use
P value
Mean length of hospital stay 7.05 days 6.88 days 0.145
Mean hospital mortality rate 0.78% 0.70% 0.509
Mean general hAI rate 3.78% 3.73% 0.984
number of gnB isolates causing hAI 229 (50.7%) 224 (54.8%) 0.228
Abbreviations: hAI, healthcare-associated infections; gnB, gram-negative bacilli.
With regard to antimicrobial consumption, there was a nota-
ble and significant drop in the consumption of cefepime after its 
use was restricted, and a significant increase in the consumption 
of amikacin. Other antibiotics that presented statistically signifi-
cant increased consumption after cefepime use was restricted 
were aztreonam, ertapenem and   levofloxacin. The consumption 
of imipenem and colistin was lower, in relation to the first study 
period, after cefepime use was restricted (Table 2).
The GNB with occurrences of more than 30 isolates 
(and for which antimicrobial susceptibilities were therefore 
  analyzed) were the same in the two study periods:   Acinetobacter 
  baumanii, Pseudomonas aeruginosa,   Klebsiella pneumoniae 
and   Enterobacter spp. In the second period (after cefepime 
use was restricted), it was observed that the susceptibility for 
A. baumanii improved in relation to gentamicin and wors-
ened in relation to imipenem. For P . aeruginosa, there was no 
change in antimicrobial susceptibilities after cefepime use was 
restricted. For K. pneumoniae and Enterobacter spp, there were 
improvements in the susceptibility relating to ciprofloxacin, 
after cefepime use was restricted. Table 3 shows comparisons 
of the antimicrobial susceptibilities for the GNB studied in the 
two study periods.
Discussion
The growing resistance to antimicrobials presented by the 
bacterial agents involved in healthcare-associated infections 
has been shown to be a very important problem over recent 
decades, particularly with regard to GNB.1,3 Strategies for 
rationalizing antimicrobial prescriptions within hospital 
environments and for changing the pattern of prescriptions 
for this class of drugs have been used as tools for combating 
the constant emergence of resistance among GNB.6
Analysis of the antimicrobial consumption data in the 
two study periods showed firstly that the policy of restriction 
of cefepime use that was instituted in the hospital was effec-
tive, considering that the mean monthly consumption of this 
antibiotic went down from 159.57 DDD per 1000 patient-days 
in the first period to 13.45 DDD per 1000 patient-days in the 
second period, and this change was statistically significant. 
The observed significant increase in amikacin consumption 
in the second period, from a monthly mean of 13.03 DDD per 
1000 patient-days to 93.79 DDD per 1000 patient-days can be 
explained by its role in the second study period as a standard 
antibiotic, replacing cefepime, for empirical treatment of 
surgical site infections. A drop in imipenem consumption was 
also observed after this restriction was implemented. This, in 
turn, correlated more with the increased consumption of ertap-
enem in the second study period than with the restriction on 
cefepime use. In the hospital where this study was conducted, 
ertapenem was introduced in March 2006 as the antibiotic of 
choice for treating infections caused by extended spectrum 
beta lactamase (ESBL)-producing Enterobacteriaceae, and 
the results from the impact of this introduction, particularly 
regarding the antimicrobial susceptibility of P . aeruginosa, 
have already been published.13–15 Analysis of the consump-
tion of aztreonam, colistin and levofloxacin showed that 
although there was a statistically significant change between 
the two periods, the consumption of these drugs was very low 
throughout the study, compared with the consumption of other 
antibiotics, thus diminishing the importance of this finding. 
On the other hand, the consumption of ciprofloxacin went up 
from a monthly mean of 38.61 DDD per 1000 patient-days to 
50.89 DDD per 1000 patient-days after restriction of cefepime 
use. This increasing trend may be related to changes in the 
sensitivity of GNB in the second study period, since there 
were improvements in the antimicrobial susceptibilities of K. 
pneumoniae and Enterobacter spp in the period following the 
restriction of cefepime use.
For A. baumanii, the analysis of the antimicrobial suscep-
tibility showed that there was a significant improvement in 
susceptibility in relation to gentamicin and worsening in rela-
tion to imipenem, although there were no differences in the 
consumption of these antimicrobials in the hospital. Despite 
the restriction on cefepime use, there was no change in the 
susceptibility of A. baumanii in relation to this antimicrobial. 
Regarding the susceptibility of P . aeruginosa, analysis and 
comparison of the data from the two study periods showed 
that there was no change after cefepime use was restricted, Infection and Drug Resistance 2011:4 submit your manuscript | www.dovepress.com
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Table 2 comparison of the antimicrobial susceptibilities among the main gnB species involved in nosocomial infections, between the 
periods preceding and subsequent to restriction on cefepime use
Pathogen/Antibiotic (number  
of isolates tested before/after  
restriction on cefepime use)
Susceptibility (%) in 24-month  
period preceding restriction  
on cefepime use
Susceptibility (%) in 24-month  
period subsequent to restriction  
on cefepime use
P value
A. baumanii
Amikacin (58/35) 13.8 14.3 .0.999
Ampicillin/sulbactam (11/37) 90.9 78.4 0.662
cefepime (50/35) 6 8.6 0.687
ceftazidime (58/29) 8.6 6.9 .0.999
ceftriaxone (48/37) 4.2 2.7 ,0.999
Ciprofloxacin (48/30) 12.5 6.7 0.704
gentamicin (57/37) 22.8 56.8 0.001
Imipenem (47/37) 95.7 56.8 ,0.001
Trimethoprim-sulfamethoxazole (48/35) 18.8 14.3 0.592
P. aeruginosa
Amikacin (44/42) 75 66.7 0.395
cefepime (30/41) 80 63.4 0.130
ceftazidime (44/41) 61.4 65.9 0.667
Ciprofloxacin (31/40) 64.5 57.5 0.549
gentamicin (43/41) 74.4 63.4 0.276
Imipenem (30/42) 83.3 66.7 0.114
Piperacillin/Tazobactam (7/36) 57.1 66.7 0.680
K. pneumoniae
Amikacin (39/29) 84.6 86.2 .0.999
cefepime (20/29) 25 31 0.646
ceftazidime (22/20) 18.2 25 0.714
cefotaxime (20/15) 15 33.3 0.246
ceftriaxone (19/14) 15.8 21.4 .0.999
Ciprofloxacin (36/29) 27.8 51.7 0.049
gentamicin (39/29) 23.1 34.5 0.300
Imipenem (22/29) 100 100 *
Piperacillin/Tazobactam (3/20) 33.3 20 .0.999
Trimethoprim-sulfamethoxazole (39/29) 46.2 62.1 0.193
Enterobacter spp
Amikacin (32/37) 78.1 86.5 0.361
cefepime (22/37) 72.7 75.7 0.801
ceftazidime (26/32) 69.2 78.1 0.442
cefotaxime (21/23) 47.6 69.6 0.139
ceftriaxone (10/14) 50 48.1 0.421
Ciprofloxacin (27/37) 48.1 73 ,0.043
gentamicin (31/37) 83.9 83.8 0.992
Imipenem (27/37) 100 100 *
Trimethoprim-sulfamethoxazole (32/37) 32 37 0.227
Note: *P values not able to be calculated because there were no cases of resistance.
Abbreviation: gnB, gram-negative bacilli.
for any of the antibiotics tested. For K. pneumoniae and 
  Enterobacter spp, comparison of the susceptibilities data 
showed that there were significant improvements in the sus-
ceptibilities of these bacterial agents in relation to ciprofloxa-
cin, in the second study period, although the consumption 
of this antimicrobial increased in this period. Comparison 
between these results and those from previous studies, regard-
ing the impact of changes in antimicrobial prescriptions on 
the   sensitivity profile of GNB involved in hospital infections 
shows the complexity of this interaction, given that changes 
in the use of a single class of antimicrobials may produce 
different changes in relation to the susceptibilities of the 
bacterial agents studied.6,16–19
Between the two study periods, there was no difference 
in the patients’ mean length of hospital stay or in the hospital 
mortality rate. Likewise, there was no significant difference 
in the nosocomial infection incidences. These data make it 
possible to infer indirectly that the severity of the   hospitalized Infection and Drug Resistance 2011:4 submit your manuscript | www.dovepress.com
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Table 3 comparison of mean monthly consumption, in DDD/1000 patient-days, of antimicrobials with a spectrum of action directed 
against gnB, between the periods preceding and subsequent to restriction of cefepime use
Antimicrobial Mean monthly consumption  
in the 24-month period preceding  
restriction on cefepime use
Mean monthly consumption  
in the 24-hour period subsequent  
to restriction on cefepime use
P value
Amikacin 13.03 93.79 ,0.001
Ampicillin/sulbactam 76.62 66.64 0.156
Aztreonam 0.44 0.78 0.005
cefepime 159.57 13.45 ,0.001
ceftriaxone 57.86 50.47 0.119
ceftazidime 28.59 25.90 0.968
Ciprofloxacin 38.61 50.89 0.075
colistin 0.86 0.01 ,0.001
ertapenem 10.05 20.50 0.003
gentamicin 68.24 61.38 0.298
Imipenem 36.53 15.02 ,0.001
Levofloxacin 1.29 2.73 0.020
Meropenem 14.76 17.56 0.589
Piperacillin/Tazobactam 1.46 2.15 0.136
Polymyxin B 0.07 0.03 0.555
Abbreviations: GNB, Gram-negative bacilli; DDD/1000, defined daily dose per thousand.
patients’ conditions was probably similar between the two 
periods, and that the prevalence of nosocomial infection 
among the hospitalized patients was also similar between 
the two periods. This is important because differences in the 
severity of patients’ conditions or in the prevalence of noso-
comial infection among patients may influence the variations 
in bacterial susceptibilities described above.
The limitations of ecological studies for analyzing 
relationships between antimicrobial consumption and the 
development of bacterial resistance within hospital environ-
ments have already been explored.20 Bacterial resistance 
is directed by the principles of natural selection, and its 
underlying selection and dispersion mechanisms are mat-
ters of great complexity. The influence of antimicrobial 
consumption on this resistance may even have different 
effects over the course of time, and will be most important 
at the time when a specific resistance mechanism appears. 
Regarding the analysis of bacterial susceptibilities, the cut-
off points established by the CLSI for defining resistance, 
as used in these types of study, are very high and exclude 
bacterial strains with low resistance levels from the analysis. 
Such strains usually precede strains with high resistance 
levels and would also be important in analyses of hospital 
environments.21
One limitation in particular in this study was the absence 
of molecular biology analysis of the bacteria involved, 
which would have made it possible to evaluate whether the 
observed differences in antimicrobial susceptibility were 
caused by the introduction of new bacterial strains or by 
clonal   expansion. Another deficiency was the lack of mea-
surements on   healthcare professionals’ adherence to hospital 
infection control practices in the two study periods. Although 
the recommendations for such practices remained the same 
throughout the two periods, differences in adherence to the 
recommendations may have influenced the results obtained.
The results from this study suggest that the restriction 
on cefepime use had a positive impact on the sensitivity 
profiles of the K. pneumoniae and Enterobacter spp strains 
involved in healthcare-associated infections at the orthopedic 
hospital where this study was conducted, given that after the 
restriction was introduced, the susceptibility to ciprofloxacin 
improved. However, for A. baumanii, the results suggest 
that there was a negative impact, given the worsening of 
susceptibility to imipenem.
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